

# Augmentation and Combination Strategies in Treatment-Resistant Depression

Maurizio Fava, M.D.

A substantial proportion of depressed patients show only partial or no response to antidepressants, and even among responders to antidepressant treatment, residual symptoms are rather common. When depressions do not respond adequately to treatment with an antidepressant, clinicians may choose to keep the same antidepressant and add another “augmenting” compound. Such augmentation strategies involve the use of a pharmacologic agent that is not considered to be a standard antidepressant but may boost or enhance the effect of an antidepressant. Alternatively, clinicians may choose combination strategies, in which they combine the antidepressant that did not produce adequate response with another antidepressant, typically of a different class. There are only a few controlled clinical trials of these 2 strategies among patients with treatment-resistant depression or among patients who have only partially benefited from antidepressant treatment. Most of the time, clinicians’ decisions are, therefore, guided by anecdotal reports, case series, and by some relatively smaller, uncontrolled clinical trials. These augmentation and combination strategies appear to be relatively safe and effective approaches to treatment-resistant depressions, although there is a relative paucity of controlled studies to support their efficacy. These strategies typically aim at obtaining a different neurochemical effect than the one obtained with the antidepressant that has not produced adequate response. While drug-drug interactions may limit the use of some of these strategies, the potential loss of partial benefit from the failed drug inherent in switching may increase the acceptability of augmentation and combination strategies among partial responders. Further studies are clearly needed to evaluate the comparative efficacy and tolerability of these different approaches in treatment-resistant depressions.

(*J Clin Psychiatry* 2001;62[suppl 18]:4–11)

Several studies suggest that 29% to 46% of depressed patients show only partial or no response to antidepressants,<sup>1</sup> and even among responders to antidepressant treatment, residual symptoms are common<sup>2</sup> and have been shown to be associated with greater likelihood of relapsing and perhaps having a poorer prognosis.<sup>3</sup> While there are many good studies showing the efficacy of antidepressants in placebo-controlled trials of outpatients or inpatients with major depressive disorder, there are only a few controlled clinical trials among patients with treatment-resistant depression or among patients who have only partially benefited from antidepressant treatment. Most of the time, clinicians’ decisions are guided by anecdotal reports, case series, and relatively small, uncontrolled clinical trials. When one surveys psychiatrists to assess their perceptions of what treatments are effective in treatment-resistant depression, in the absence of data on the newer

strategies, the best-studied strategies to manage patients with partial or no response do not seem to reflect current psychopharmacologic practice.<sup>4</sup>

When depressed patients do not respond adequately to treatment with an antidepressant, clinicians may choose to keep the same antidepressant and add another “augmenting” compound. Such augmentation strategies involve the use of a pharmacologic agent that is not considered to be a standard antidepressant but that may boost or enhance the effect of an antidepressant. Alternatively, clinicians may choose to combine the antidepressant that did not produce adequate response with another antidepressant, typically of a different class. The popularity of these combination strategies has increased over time with the introduction of newer antidepressants that have fairly benign side effect profiles and are associated with fewer concerns about drug-drug interactions. My colleagues and I<sup>5</sup> recently surveyed 402 psychiatrists from all over North America, asking them what they would do when a patient fails to respond to 8 weeks or more of an adequate dose of a selective serotonin reuptake inhibitor (SSRI); even though the most- and best-studied strategies are lithium and thyroid augmentation, the approaches combining either bupropion or a tricyclic antidepressant (TCA) with an SSRI were the first and third most popular augmentation/combination strategies. These findings confirm the impression

---

*From the Depression Clinical and Research Program, Massachusetts General Hospital, Boston.*

*Presented at the planning teleconference “Management of Treatment-Resistant Depression,” which was held October 18, 2000, and supported by an unrestricted educational grant from Eli Lilly and Company.*

*Reprint requests to: Maurizio Fava, M.D., Depression Clinical and Research Program, Massachusetts General Hospital—ACC 812, 15 Parkman St., Boston, MA 02114.*

that there is indeed a discrepancy between how physicians treat nonresponders and what is recommended in the literature.

Augmentation and combination strategies are often favored by clinicians over switching in the case of partial response, since patients may be reluctant to discontinue an antidepressant that has produced some benefit. On the other hand, a recent study by Joffe and Levitt<sup>6</sup> has shown in a reanalysis of 2 double-blind trials that the augmentation response is not related to the degree of nonresponse to the preceding antidepressant trial, with partial and nonresponders having comparable chances of response.

This article will review some of the studies concerning both augmentation and combination strategies in treatment-resistant depression.

## AUGMENTATION STRATEGIES

### General Principles

Over the past few decades, numerous compounds have been used as augmenting agents with antidepressants. Although the majority of the studies of this therapeutic approach are open-label, many investigations are also double-blind, often placebo-controlled, allowing us to draw relatively firm conclusions on the efficacy of some of the augmenting agents, such as lithium and thyroid hormones. It appears that the improvement following antidepressant augmentation tends to occur within 3 to 4 weeks, so it may be too premature to decide in the first few days or couple of weeks whether an augmentation strategy is working. Almost all the studies on the efficacy of these augmentation strategies have focused on the short-term outcome, and very little is known about the minimum duration of the augmentation trial in responders to such strategy. A typical approach is to maintain the augmenting agent for 6 to 9 months after obtaining remission and then to attempt a gradual discontinuation of the augmenting agent.

### Lithium

Lithium augmentation is not as popular now as it was in the 1980s, although many studies have clearly shown that the addition of 600 mg/day or more of lithium, typically in divided doses and with adequate blood levels, leads to a robust increase in the chances of response in treatment-resistant patients who do not respond to TCAs, monoamine oxidase inhibitors (MAOIs), or SSRIs.<sup>7-13</sup> Eleven double-blind controlled trials of lithium augmentation in depression have been published; of those, 10 reported the observed response rate, which averaged 52% for a total of 135 lithium-treated patients.<sup>13-24</sup> Why is it that in spite of these studies, lithium is not often used? In 2 studies, lithium led to little antidepressant response when added to SSRIs.<sup>15,19</sup> Furthermore, there is a risk of toxicity with lithium,<sup>25</sup> and a significant proportion of lithium-treated patients may report bothersome side effects, particularly patients who are used to the

fairly benign side effect profile of the SSRIs. Because of the need for blood monitoring and the risk of hypothyroidism, significant weight gain, and nephrotoxicity, lithium augmentation is often perceived by patients and clinicians to be not as user-friendly as other augmentation strategies. All of these reasons might contribute to lithium's diminished popularity among clinicians.

### Thyroid Hormone

In depression studies, liothyronine ( $T_3$ ) has been used in preference to thyroxine ( $T_4$ ) because of its rapid onset and offset of action.<sup>26</sup>  $T_3$  augmentation, in doses of 25 to 50  $\mu\text{g}/\text{day}$ , has been used successfully among depressed patients refractory to TCAs.<sup>17,27</sup> This strategy does not appear to be very popular today,<sup>5</sup> perhaps because all published studies concern TCAs and not SSRIs<sup>27</sup> or because thyroid augmentation is associated with the possible side effects of nervousness and insomnia.

### Buspirone

A commonly used strategy in treatment-resistant depressed patients is buspirone augmentation. Buspirone is a typically well-tolerated anti-anxiety drug, with serotonin-1A ( $5\text{-HT}_{1A}$ ) partial agonist properties. Studies using 5 to 15 mg twice a day of buspirone have shown significant improvement in treatment-resistant patients.<sup>28-31</sup> The main issue concerning the use of buspirone augmentation is its efficacy. In fact, in 1 study,<sup>32</sup> the response rate was very low among depressed patients with treatment-resistant depression, and the only placebo-controlled study in treatment-resistant depression comparing buspirone and placebo augmentation<sup>33</sup> found no statistically significant difference in response rates between these 2 treatments (51% vs. 47%, respectively). One possible advantage of buspirone augmentation is that the addition of this compound has been shown to be more effective than placebo in alleviating SSRI-induced sexual dysfunction among treatment-resistant depressed patients.<sup>34</sup>

### Pindolol

Pindolol augmentation is rarely used in the United States, but is relatively more popular in Europe and Canada. Pindolol is a  $\beta$ -blocker and a  $5\text{-HT}_{1A}$  antagonist. A dose of 2.5 mg 3 times a day has been used in most studies. This agent has generated a lot of interest because it has been shown to accelerate antidepressant response when combined with SSRIs in some,<sup>35-39</sup> but not all<sup>40</sup> the studies. A study by Moreno and colleagues<sup>41</sup> found no response among 10 refractory depressed patients, and a study by Perez and colleagues<sup>42</sup> showed no difference from placebo in a very short (10-day) trial of augmentation in a refractory depressed population. Another issue concerning the use of this augmentation strategy is that findings by Blier and Bergeron<sup>39</sup> have shown some increased irritability with the use of pindolol in treatment-resistant depression.

## Dopaminergic Drugs

Augmentation with dopaminergic drugs is an interesting strategy. In an open trial, Bouckoms and Mangini<sup>43</sup> used with some success the antiparkinsonian drug pergolide, 0.25 to 2 mg/day. Similarly, there are reports of the usefulness of antidepressant augmentation with the dopaminergic drugs amantadine (100–200 mg twice a day)<sup>44</sup> and pramipexole (0.125–0.25 mg 3 times a day).<sup>45</sup> A recent prospective, open study of pramipexole (mean dose = 0.84 mg/day) augmentation of TCAs and SSRIs showed a 55% response rate among 31 inpatients with unipolar or bipolar depression.<sup>46</sup> Unfortunately, these studies concerning the augmentation of antidepressants with dopaminergic agents are uncontrolled and have relatively small sample sizes. The effectiveness of these augmenting agents, therefore, remains to be established. The use of dopaminergic drugs as augmentors of antidepressants may offer a theoretical advantage in that dopamine in animal models may stimulate sexual function and that these agents have been shown anecdotally to alleviate the sexual dysfunction induced by SSRIs.<sup>45</sup>

## Psychostimulants

In line with the potential role of dopaminergic agents as augmentors of antidepressants, psychostimulants, which have significant effects on dopamine neurotransmission, have been used to augment TCAs,<sup>47</sup> MAOIs,<sup>48</sup> SSRIs,<sup>49,50</sup> and even venlafaxine.<sup>51</sup> Clinicians typically use methylphenidate, 10 to 40 mg/day, or dextroamphetamine, 5 to 20 mg/day, in divided doses. The main issues concerning the use of psychostimulant augmentation are the potential for abuse in some patients with history of substance abuse and the relatively short half-life of psychostimulants. Psychostimulants may also worsen anxiety and irritability and may cause significant insomnia; therefore, it is important to prescribe the use of stimulants earlier and not later during the day. Even though the response may be transient,<sup>48</sup> these agents tend to work quite rapidly as augmentors.

## Modafinil

Modafinil is a novel psychostimulant with pharmacologic actions somewhat different from those of the amphetamines. In a retrospective case series, Menza et al.<sup>52</sup> reported the usefulness of modafinil (in doses up to 200 mg/day) as an adjunct to antidepressants in refractory depression. A recent report by DeBattista et al.<sup>53</sup> showed that 57% of 14 patients not responding to SSRIs or venlafaxine regarded themselves as much improved following augmentation with up to 400 mg/day of modafinil. The effectiveness of modafinil as an augmenting agent remains to be established, since these studies concerning its use are uncontrolled and have relatively small sample sizes.

## Atypical Antipsychotics

Both risperidone<sup>54</sup> and olanzapine<sup>55</sup> have shown good responses in some small trials in SSRI nonresponders. The

typical doses in augmentation of antidepressants are 0.5 to 2 mg/day for risperidone and 5 to 20 mg/day for olanzapine. In addition, olanzapine augmentation has been shown to be efficacious in a placebo-controlled study of refractory obsessive-compulsive disorder,<sup>56</sup> and the combination of fluoxetine and olanzapine has produced marked increases in the levels of dopamine, serotonin, and norepinephrine in the prefrontal cortex of the rat.<sup>57</sup> The rapid anti-anxiety and anti-irritability effects of these drugs have made them relatively popular among clinicians in the treatment of agitated or insomniac refractory patients. The main disadvantage of these strategies is the risk of sedation and weight gain.

## Anticonvulsants

Many of the anticonvulsants used in bipolar illness (i.e., valproic acid, carbamazepine, lamotrigine, gabapentin, and topiramate) are also used as adjuncts in resistant unipolar depression, although there are no studies in the literature on this strategy. The main issues with this strategy are sedation and, in the case of valproic acid and carbamazepine, the need for blood monitoring.

## Inositol

Despite initial anecdotal positive reports of the usefulness of augmentation of antidepressants with doses of inositol up to 12 g/day, a recent controlled, double-blind augmentation trial did not support its use in SSRI treatment failures,<sup>58</sup> and a study by Levine et al.<sup>59</sup> showed no difference in outcome between patients treated with SSRIs and placebo versus those treated with SSRIs and inositol.

## Opiates

There is very modest evidence, mostly based on case reports and case series, for the usefulness of augmentation of antidepressants with opiates, such as oxycodone, oxycodone,<sup>60</sup> and buprenorphine.<sup>61</sup> The lack of adequate studies and the potential risk for abuse markedly limit the use of these augmenting agents.

## Estrogen

Estrogen exerts profound effects on behavior by interacting with neuronal estrogen receptors.<sup>62</sup> There is mostly anecdotal evidence for the efficacy of estrogen augmentation of antidepressants in resistant depression among postmenopausal women. In addition, as pointed out by Stahl<sup>63</sup> in his review of the literature, there are no guidelines on how to optimize antidepressant administration with estrogen, especially in women insufficiently responsive to antidepressants.

## Dehydroepiandrosterone (DHEA)

DHEA, a major circulating corticosteroid in humans, has an unclear physiologic role. In addition to serving as a precursor to testosterone and estrogen, DHEA and its sulfated metabolite, DHEA-S, most likely have important

biological roles and have been hypothesized to be involved in regulating mood and sense of well-being.<sup>64</sup> A very small, preliminary, double-blind study suggests its usefulness up to 90 mg/day as an adjunct to antidepressants in refractory depression.<sup>64</sup> Further studies are clearly necessary, given the small number of patients studied.

### Folate and S-Adenosyl-Methionine (S-AMe)

Folate, in particular its active form methyltetrahydrofolate (MTHF), and S-AMe are compounds closely involved in the one carbon cycle and in methylation processes of the brain. These compounds have been studied extensively in depression, and the literature suggests that they may have antidepressant properties.<sup>65,66</sup> An open trial of methylfolate (up to 30 mg/day) in SSRI-refractory patients suggested its usefulness as an adjunct,<sup>67</sup> and a recent study by Coppen and Bailey<sup>68</sup> showed that adding folate (0.5 mg/day) to fluoxetine led to significantly higher response rates among depressed women (but not among depressed men) than fluoxetine plus placebo. A double-blind study showed an earlier onset of efficacy among patients receiving treatment with the TCA imipramine plus S-AMe compared with patients treated with imipramine and placebo.<sup>69</sup> However, there have been no studies of S-AMe augmentation of antidepressants in resistant depression, despite some positive anecdotal experiences.

### Omega-3 Fatty Acids

Given the recent report of the usefulness of omega-3 fatty acids in improving the short-term course of illness among patients with bipolar disorder,<sup>70</sup> there has been an increased interest in the use of natural compounds as augmentors of antidepressants in treatment-resistant major depressive disorder. Unfortunately, there are no published studies of the use of these augmenting agents.

Table 1 provides a summary of the pertinent review of the literature concerning augmentation strategies in treatment-resistant depression.

## COMBINATION STRATEGIES

### General Principles

Combination strategies are those involving the concomitant use of 2 agents with well-established antidepressant efficacy. Although the combination of MAOIs and TCAs was used in the 1970s and early 1980s in treatment-resistant depression, the risk of lethal hypertensive crises related to drug-drug interactions and the introduction of newer antidepressants have led to the disappearance of this combination from clinical practice. The typical rationale of combination strategies is that of broadening the central nervous system (CNS) effect by combining agents affecting different neurotransmitter systems. While there are numerous double-blind studies of augmentation strategies, there are only 2 double-blind studies of combination

**Table 1. Overview of Augmentation Strategies<sup>a</sup>**

Efficacy	Augmentation Strategy
Clear	Lithium, T <sub>3</sub>
Suggested	Dopaminergic agents, psychostimulants, atypical antipsychotics, folate/methylfolate
Anecdotal	Modafinil, anticonvulsants, opiates, S-AMe, DHEA, estrogens
Disputed	Buspirone, pindolol, inositol

<sup>a</sup>Abbreviations: DHEA = dehydroepiandrosterone, S-AMe = S-adenosyl-methionine, T<sub>3</sub> = liothyronine.

strategies, reflecting the need for further study in this area. It appears that the improvement following the combination of antidepressants tends to occur within 4 to 6 weeks, so it may be premature to decide in the first few days or couple of weeks whether a combination strategy is working. Almost all the studies on the efficacy of these strategies have focused on the short-term outcome, and very little is known about the minimum duration of combination trials in responders to such strategies. A typical approach is to maintain the combination for 6 to 9 months after obtaining remission and then to attempt a gradual discontinuation of 1 of the 2 antidepressants.

### Bupropion and SSRIs

As mentioned above, bupropion (sustained-release formulation, 100–150 mg once or twice a day) combined with SSRIs was the first strategy chosen by the psychiatrists that we surveyed.<sup>5</sup> On the other hand, the evidence for this combination is based primarily on anecdotal reports, case series, or small open trials.<sup>71–74</sup> The main disadvantages of this approach are that the combination of bupropion and SSRIs may lead to tremor<sup>73</sup> or panic attacks.<sup>75</sup> However, the positive effects of bupropion on SSRI-induced sexual dysfunction reported in some studies<sup>76,77</sup> may be a significant advantage for this strategy.

### Mirtazapine and SSRIs

Mirtazapine is a dual-action antidepressant that increases both serotonergic and noradrenergic activity by blocking the  $\alpha_2$ -adrenergic autoreceptors and heteroreceptors and the serotonergic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors. Mirtazapine (15–30 mg q.h.s.) combined with SSRIs has been reported to be helpful in an open study of nonresponders to SSRIs<sup>78</sup> and to be more effective than placebo plus SSRIs in a subsequent double-blind study of refractory depressed patients.<sup>79</sup> A recent study by Debonnel et al.<sup>80</sup> showed a significantly higher response rate to the combination of paroxetine and mirtazapine than monotherapy with either drug and a 64% response rate to the switch to combination therapy for patients not responding to monotherapy. The combination of mirtazapine and SSRIs may also help manage SSRI-induced sexual dysfunction.<sup>81</sup> The main disadvantages of this strategy are the weight gain and sedation that have been reported with its use.<sup>78</sup>

### Desipramine or Other TCAs and SSRIs

An early study by Nelson et al.<sup>82</sup> showed that the TCA-plus-SSRI combination may produce a rapid onset of action, while a more recent study by the same author<sup>83</sup> has shown that remission rates are significantly higher with desipramine plus fluoxetine than with either drug alone. This is consistent with reports that desipramine and other TCAs were effective in combination with SSRIs in small cohorts of patients.<sup>84–86</sup> The main issue related to combining TCAs with SSRIs is that TCAs are substrates of the cytochrome P450 2D6 isoenzyme (CYP2D6), so there may be accumulation of TCAs when coadministered with SSRIs, which inhibit this pathway, potentially leading to cardiac toxicity. Low doses of TCAs (25–75 mg/day) are therefore typically used, and monitoring of blood TCA levels is necessary. Despite the promising response rates reported in previous open trials, in a double-blind study from our group,<sup>15</sup> we observed fairly low response rates with desipramine (up to 50 mg/day) combined with fluoxetine among patients who had not responded to 8 weeks of fluoxetine, 20 mg/day.

### Reboxetine and SSRIs

After an initial anecdotal report from our group<sup>87</sup> that the addition of reboxetine, a relatively selective norepinephrine reuptake inhibitor, was helpful in patients resistant to SSRI treatment, 2 open trials, using doses up to 8 mg/day, have suggested the usefulness of this agent combined with SSRIs in refractory depression.<sup>88,89</sup> The hypothesis by Nelson<sup>90</sup> that combining drugs that affect both serotonin and norepinephrine may be uniquely helpful among nonresponders to drugs that affect only the serotonergic system may provide further support to the use of this strategy. Furthermore, there is one drug-drug interaction study of fluoxetine and reboxetine suggesting safety of this combination.<sup>91</sup>

### Nefazodone and SSRIs

There have been only anecdotal reports suggesting the efficacy of combining SSRIs with nefazodone, typically 100 or 200 mg twice a day. One possible issue concerning this strategy is related to some reports of serotonin syndrome,<sup>92,93</sup> not particularly severe, due to the fact that nefazodone is a mildly potent uptake blocker of serotonin. The biotransformation pathways of nefazodone are mediated mainly by the CYP3A system, whereas clearance of meta-chlorophenylpiperazine (*m*-CPP), a nefazodone metabolite, is mediated by CYP2D6.<sup>94</sup> Therefore, when nefazodone is coadministered with SSRIs that inhibit the CYP2D6 system, there may be an accumulation of *m*-CPP, which by itself may cause some irritability and anxiety in some patients.<sup>95</sup> The advantage of adding nefazodone to SSRIs in the event of nonresponse is that it has been shown, again anecdotally, to alleviate sexual dysfunction related to treatment with SSRIs.<sup>96</sup>

Table 2. Overview of Combination Strategies<sup>a</sup>

Efficacy	Combination Strategy
Suggested	Bupropion and SSRIs, mirtazapine and SSRIs, desipramine or TCAs and SSRIs, reboxetine and SSRIs
Anecdotal	Venlafaxine and SSRIs, nefazodone and SSRIs
Disputed	SSRIs and SSRIs

<sup>a</sup>Abbreviations: SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant.

### Venlafaxine and SSRIs

There are only anecdotal reports of venlafaxine augmentation (75–300 mg/day) in SSRI nonresponders. The main disadvantage is that venlafaxine is a substrate of CYP2D6, and there have been reports of accumulation of venlafaxine when coadministered with some SSRIs inhibiting the 2D6 pathway, leading to serotonin syndrome<sup>97</sup> or to marked blood pressure elevation and severe anticholinergic side effects.<sup>98</sup>

### SSRI Plus Another SSRI

Given that SSRIs vary in potency and specificity of serotonin reuptake inhibition in vitro, that paroxetine and fluoxetine are relatively more potent norepinephrine uptake inhibitors than the other SSRIs, and that sertraline is a relatively more potent dopamine uptake inhibitor than the other SSRIs,<sup>99</sup> it is not surprising that SSRIs have been anecdotally reported to be useful when combined with other SSRIs<sup>100</sup> and that this strategy has been reported to be infrequently used by clinicians in a recent survey.<sup>4</sup> The main disadvantages of this approach are an increase in the intensity of serotonergic side effects and a theoretical risk of serotonin syndrome.<sup>101</sup> A report by Bondolfi and colleagues<sup>100</sup> suggests that there may be an interesting drug-drug interaction when fluvoxamine is combined with citalopram, as the addition of fluvoxamine increases the ratio of S-citalopram versus the R-citalopram, with S-citalopram being a more potent uptake inhibitor of serotonin.

Table 2 provides a summary of the pertinent review of the literature concerning combination strategies in treatment-resistant depression.

### SUMMARY

In conclusion, many augmentation and combination strategies are available to psychopharmacologists and psychiatrists. Most of these strategies appear to be relatively safe and effective approaches to treatment-resistant or intolerant patients, although there is a paucity of controlled studies to support their efficacy. Most of these strategies aim at obtaining a different neurochemical effect than the one obtained with the antidepressant that has not produced adequate response. While drug-drug interactions may limit the use of some of the combination strategies, the potential loss of partial benefit from the failed drug may

increase their acceptability. Further studies are clearly needed to evaluate the comparative efficacy and tolerability of these different strategies.

**Drug names:** amantadine (Symmetrel and others), buprenorphine (Buprenex), bupropion (Wellbutrin), buspirone (BuSpar), carbamazepine (Tegretol and others), citalopram (Celexa), desipramine (Norpramin and others), dextroamphetamine (Dexedrine and others), fluoxetine (Prozac), fluvoxamine (Luvox), gabapentin (Neurontin), inositol (Megadose and others), lamotrigine (Lamictal), liothyronine (Cytomel, Triostat), methylphenidate (Ritalin and others), mirtazapine (Remeron), modafinil (Provigil), nefazodone (Serzone), olanzapine (Zyprexa), oxycodone (Percodan and others), oxymorphone (Numorphan), paroxetine (Paxil), pergolide (Permax), pramipexole (Mirapex), risperidone (Risperdal), sertraline (Zoloft), L-thyroxine (Levothroid, Synthroid), topiramate (Topamax), valproic acid (Depakene and others), venlafaxine (Effexor).

**Disclosure of off-label usage:** The author of this article has determined that, to the best of his knowledge, amantadine, buprenorphine, buspirone, carbamazepine, dextroamphetamine, gabapentin, inositol, lamotrigine, liothyronine, methylphenidate, modafinil, olanzapine, oxycodone, oxymorphone, pergolide, pramipexole, risperidone, L-thyroxine, topiramate, and valproic acid are not approved by the U.S. Food and Drug Administration for augmentation of antidepressants; and bupropion, citalopram, desipramine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, and venlafaxine are not approved for combination treatment in depression.

## REFERENCES

- Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatr Clin North Am* 1996;19:179–200
- Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. *J Clin Psychiatry* 1999;60:221–225
- Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. *Psychiatr Ann* 1994;42:281–290
- Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. *Harv Rev Psychiatry* 1999;6:322–326
- Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. *J Clin Psychiatry* 2000;61:403–408
- Joffe RT, Levitt AJ. Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. *J Affect Disord* 1999;52:257–259
- Johnson FN. Lithium augmentation therapy. *Rev Contemp Pharmacother* 1991;2:1–52
- Price LH. Pharmacological strategies in refractory depression. In: Tasman A, Goldfinger SM, Kaufman CA, eds. *American Psychiatric Press Review of Psychiatry*, vol 9. Washington, DC: American Psychiatric Press; 1990: 116–131
- Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depressions with tranlycypromine and lithium. *J Nerv Ment Dis* 1972; 155:216–220
- Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranlycypromine treatment in refractory depression. *Am J Psychiatry* 1985;142:619–623
- Fein S, Paz V, Rao N, et al. The combination of lithium carbonate and an MAOI in refractory depressions. *Am J Psychiatry* 1988;145:249–250
- Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. *Acta Psychiatr Scand* 1993;88:300–301
- Baumann P, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol* 1996;16:307–314
- Cournoyer G, De Montigny C, Oulette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Presented at the Congress Internationale Neuro-Psychopharmacologicum meeting; June 9–23, 1984; Florence, Italy
- Fava M, Rosenbaum J, McGrath P, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression. *Am J Psychiatry* 1994;151:1372–1374
- Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant action: an effective prescription for treatment refractory depression. *Arch Gen Psychiatry* 1983;40:1335–1342
- Joffe RT, Singer W, Levitt AJ, et al. A placebo controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993;50:387–393
- Kantor D, McNeven S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: fact or fiction? *Can J Psychiatry* 1986;31: 416–418
- Katona, CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. *Br J Psychiatry* 1995;166:80–86
- Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. *Pharmacopsychiatry* 1989;22:183–187
- Stein G, Bernadt M. Double-blind trial of lithium carbonate in tricyclic resistant depression. In: Birch NJ, ed. *Lithium: Inorganic Pharmacology and Psychiatric Use*. Oxford, UK: IRL Press; 1988:35–36
- Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. *Br J Psychiatry* 1993;162:634–640
- Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. *J Clin Psychopharmacol* 1988;8:120–124
- de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. *Arch Gen Psychiatry* 1983;40:1327–1334
- Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate [letter]. *Am J Psychiatry* 1989; 146:278
- Prange AJ Jr. Novel uses of thyroid hormones in patients with affective disorders. *Thyroid* 1996;6:537–543
- Aronson R, Offman HJ, Joffe T, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. *Arch Gen Psychiatry* 1996;53:842–848
- Jacobsen FM. Possible augmentation of antidepressant response by buspirone. *J Clin Psychiatry* 1991;52:217–220
- Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. *J Clin Psychiatry* 1993;54: 269–271
- Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. *South Afr Med J* 1997;87(4, suppl):534–537, 540
- Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. *J Clin Psychopharmacol* 1998;18:465–469
- Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. *Int Clin Psychopharmacol* 1998;13:83–86
- Landén M, Björling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. *J Clin Psychiatry* 1998;59:664–668
- Landén M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. *J Clin Psychopharmacol* 1999;19:268–271
- Perez V, Gilaberte I, Faries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. *Lancet* 1997;349:1594–1597
- Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. *Int Clin Psychopharmacol* 1997;12:81–89
- Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? *J Clin Psychopharmacol* 1997;17:446–450
- Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. *Am J Psychiatry* 1998;155: 1346–1351
- Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. *J Clin Psychiatry* 1998;59(suppl 5):16–23; discussion 24–25
- Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxe-

- tine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. *Biol Psychiatry* 1999;45:1170–1177
41. Moreno F, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. *J Clin Psychiatry* 1997;58:437–439
  42. Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. *Arch Gen Psychiatry* 1999;56:375–379
  43. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? *Psychopharmacol Bull* 1993;29:207–211
  44. Michelson D, Bancroft J, Targum S, et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. *Am J Psychiatry* 2000;157:239–243
  45. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. *Ann Clin Psychiatry* 2000;12:137–140
  46. Lattanzi L, Cassano P, Dell'Osso L, et al. Adjunctive pramipexole in treatment resistant depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  47. Wharton R, Perel J, Dayton P, et al. A potential clinical use for methylphenidate with tricyclic antidepressants. *Am J Psychiatry* 1971;127:1619–1625
  48. Fawcett J, Kravitz HM, Zajecka MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. *J Clin Psychopharmacol* 1991;11:127–132
  49. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. *J Clin Psychiatry* 1996;57:72–76
  50. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  51. Bader G, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. *J Clin Psychopharmacol* 1998;18:255–256
  52. Menza MA, Kaufman KR, Castellanos AM. Modafinil augmentation of antidepressant treatment in depression. *J Clin Psychiatry* 2000;61:378–381
  53. DeBattista C, Solvason HB, Flores BH, et al. Modafinil as an adjunctive agent in the treatment of fatigue and hypersomnia associated with depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  54. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. *J Clin Psychiatry* 1999;60:256–259
  55. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001;158:131–134
  56. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: a placebo-controlled trial. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  57. Zhang W, Pery KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. *Neuropsychopharmacology* 2000;23:250–262
  58. Nemets B, Mishory A, Levine J, et al. Inositol addition does not improve depression in SSRI treatment failures. *J Neural Transm* 1999;106:795–798
  59. Levine J, Mishori A, Susnosky M, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. *Biol Psychiatry* 1999;45:270–273
  60. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression [letter]. *Am J Psychiatry* 1999;156:2017
  61. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. *J Clin Psychopharmacol* 1995;15:49–57
  62. Stahl SM. Basic psychopharmacology of antidepressants, pt 2: estrogen as an adjunct to antidepressant treatment. *J Clin Psychiatry* 1998;59(suppl 4):15–24
  63. Stahl SM. Augmentation of antidepressants by estrogen. *Psychopharmacol Bull* 1998;34:319–321
  64. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. *Am J Psychiatry* 1999;156:646–649
  65. Alpert JE, Mischoulon D, Nierenberg AA, et al. Nutrition and depression: focus on folate. *Nutrition* 2000;16:544–546
  66. Spillmann M, Fava M. S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status. *CNS Drugs* 1996;6:416–425
  67. Alpert JE, Pingol MG, Rankin MA, et al. Methylfolate as an adjunct in SSRI refractory depression. In: *Syllabus and Proceedings Summary of the 1999 Annual Meeting of the American Psychiatric Association*; May 15–20, 1999; Washington, DC; No. 75:32
  68. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. *J Affect Disord* 2000;60:121–130
  69. Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. *Psychiatry Res* 1992;44:257–262
  70. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial [see comments]. *Arch Gen Psychiatry* 1999;56:407–412
  71. Marshall RD, Randall D, Johannet CM, et al. Bupropion and sertraline combination treatment in refractory depression. *J Psychopharmacol* 1995;9:284–286
  72. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. *J Clin Psychopharmacol* 1996;16:80–81
  73. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. *J Clin Psychiatry* 1997;58:137–145
  74. Spier SA. Use of bupropion with SRIs and venlafaxine. *Depress Anxiety* 1998;7:73–75
  75. Young SJ. Panic associated with combining fluoxetine and bupropion [letter]. *J Clin Psychiatry* 1996;57:177–178
  76. Labbate LA, Grimes JB, Hines A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. *Ann Clin Psychiatry* 1997;9:241–245
  77. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. *J Clin Psychiatry* 1998;59:112–115
  78. Carpenter LL, Jovic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry* 1999;60:45–49
  79. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  80. Debonnel G, Gobbi G, Turcotte J, et al. The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  81. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. *J Clin Psychiatry* 1999;60:260–261
  82. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. *Arch Gen Psychiatry* 1991;48:303–307
  83. Nelson JC. Combined drug treatments: pros and cons. In: *Syllabus and Proceedings Summary of the 1999 Annual Meeting of the American Psychiatric Association*; May 15–20, 1999; Washington, DC. No. 8C:227
  84. Seth R, Jennings AL, Bindman J, et al. Combination treatment with norepinephrine and serotonin reuptake inhibitors in resistant depression. *Br J Psychiatry* 1992;161:562–565
  85. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. *Ann Clin Psychiatry* 1991;3:209–214
  86. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. *J Clin Psychiatry* 1995;56:338–343
  87. Fava M. New approaches to the treatment of refractory depression. *J Clin Psychiatry* 2000;61(suppl 1):26–32
  88. Hawley CJ, Sivakumaran T, Ochocki M, et al. Co-administration of reboxetine and serotonin selective reuptake inhibitors in treatment-resistant patients with major depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  89. Dursun SM, Devarajan S. The efficacy and safety of reboxetine plus citalopram in treatment-resistant depression: an open, naturalistic case series. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10–14, 2000; San Juan, Puerto Rico
  90. Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. *J Clin Psychiatry* 1998;59(suppl 5):65–68; discussion 69
  91. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective

- norepinephrine reuptake inhibitor for the treatment of patients with depression. *Clin Pharmacokinet* 2000;39:413–427
92. Smith DL, Wenegrat BG. A case report of serotonin syndrome associated with combined nefazodone and fluoxetine [letter]. *J Clin Psychiatry* 2000;61:146
  93. John L, Perreault MM, Tao T, et al. Serotonin syndrome associated with nefazodone and paroxetine. *Ann Emerg Med* 1997;29:287–289
  94. von Moltke LL, Greenblatt DJ, Granda BW, et al. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. *Psychopharmacology (Berl)* 1999;145:113–122
  95. Sevy S, Brown SL, Wetzler S, et al. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. *Psychiatry Res* 1994;53:219–229
  96. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone [letter]. *J Clin Psychiatry* 1997;58:89
  97. Bhatara VS, Magnus RD, Paul KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. *Ann Pharmacother* 1998;32:432–436
  98. Benazzi F. Venlafaxine-fluoxetine interaction. *J Clin Psychopharmacol* 1999;19:96–98
  99. Fava M, Rosenbaum JF. Pharmacotherapy and somatic therapies. In: Beckham EE, Leber WR, eds. *Handbook of Depression*. New York, NY: Guilford Publications; 1995:280–301
  100. Bondolfi G, Chautems C, Rochat B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. *Psychopharmacology (Berl)* 1996;128:421–425
  101. Gillman PK. Serotonin syndrome: history and risk. *Fund Clin Pharmacol* 1998;12:482–491

Copyright 2001 Physicians Postgraduate Press, Inc.  
 One personal copy may be printed